iNKT cells can be activated by direct interaction with tumor cells: CD1d+ tumor cells present endogenous glycolipids via CD1d which is then recognized by the T-cell receptor of iNKT cells leading to perforin/granzyme B or Fas/FasL-mediated cytotoxicity. Here, CD1D is linked to neoplasm.